Top Research Reports For ExxonMobil, AT&T & Barclays

Monday, October 1, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today." data-reactid="23">The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see

all of today’s research reports here >>>

Buy-ranked 

ExxonMobil’s shares have gained +16.1% over the past six months, outperforming the Zacks Integrated Oil industry, which gained +12.4% over the same period. The Zacks analyst thinks the company has a leading position in the energy industry owing to its size and diverse asset base, both in terms of business mix and geographical footprint.

With a stable cash position, the company’s balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.

Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. Moreover, to address the transport constraints and pump out five times more oil from the Permian through 2025, ExxonMobil is investing billions in the basin’s midstream infrastructure.

(You can

read the full research report on ExxonMobil here >>>).

Shares of

Disney have increased +8.8% year to date, outperforming the Zacks Media Conglomerates industry’s +8.5% gain in that same time period. The Zacks analyst thinks Disney’s top-line will benefit from the solid line-up of big-budget movies slated to be released over the next 18 months.

Parks & Resorts segment continues to show robust performances both domestically and internationally owing to a rise in customer spending, higher ticket prices and attendance. ESPN+, the company’s sports streaming service, achieved the 1 million subscriber base milestone, which is positive for Disney’s upcoming direct-to-consumer service.

However, Disney’s ongoing investments on its technology platform are expected to keep margins under pressure. Additionally, higher programming costs at ESPN remains a concern. Moreover, weakness in the Consumer Products & Interactive Media segment is a headwind.

(You can

read the full research report on Disney here >>>).

Buy-ranked AbbVie’s shares have lost -2.2% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +7.1%. The Zacks analyst thinks AbbVie’s key drug, Humira has been performing well based on strong demand trends, despite new competition. " data-reactid="33">Buy-ranked 

AbbVie’s shares have lost -2.2% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +7.1%. The Zacks analyst thinks AbbVie’s key drug, Humira has been performing well based on strong demand trends, despite new competition.

Moreover, Imbruvica has multibillion-dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret’s launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market.

AbbVie has an impressive late-stage pipeline with the launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, potential biosimilar competition to Humira in Europe this year is an overhang.

(You can

read the full research report on AbbVie here >>>).

Other noteworthy reports we are featuring today include Bristol-Myers (BMY), VMware (VMW) and United Continental (UAL).

Today's Stocks from Zacks' Hottest Strategies" data-reactid="38">

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%." data-reactid="39">It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation." data-reactid="40">And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly 

Earnings Trends and 

Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please 

click here

>>>

Today's Must Read

ExxonMobil (XOM) to Gain From Oil-Rich Permian Shale Play

Disney (DIS) to Benefit from Strong Slate of Movie Titles

AbbVie's (ABBV) Pipeline Solid, Key Launches in Near Term" data-reactid="54">AbbVie's (ABBV) Pipeline Solid, Key Launches in Near Term

Featured Reports

Bristol-Myers (BMY) Boasts Solid Pipeline Amid Competition

Per the Zacks analyst, Bristol-Myers' efforts to develop its pipeline are encouraging.

Portfolio Strength, Expanding Partner Base Aids VMware (VMW)

Per the Zacks analyst, VMware's diversified product portfolio and expanding partner base that now includes AWS & IBM are driving top-line growth.

CenturyLink (CTL) Gains From Strong Network Capabilities

Per the Zacks analyst, CenturyLink's strong network capabilities, integrated hosting and network solutions designed for enterprise customers will continue to promote growth in the cloud business.

Store Openings & Distribution Centers Aid AutoZone (AZO)

Per the Zacks analyst, the opening of distribution centers and stores is developing AutoZone's supply-chain network, enabling it to offer products at the local level where customer demand is immediate.

Acquisitions Benefit BOK Financial (BOKF), Rising Costs Ail

Per the Zacks analyst, BOK Financial continues to benefit from strategic acquisitions, latest being CoBiz Financial announced in June 2018.

New Upgrades

Domestic Focus, Gas Usage Aid NextEra Energy Partners (NEP)

The Zacks analyst believes NextEra Energy Partners' decision to sell its Canadian assets to focus on domestic renewable assets coupled with the higher usage of natural gas will boost its performance.

Unit Revenues, Fleet Upgrade Buoy United Continental (UAL)

The Zacks analyst likes the company's performance with respect to unit revenues. Strong demand for air travel is aiding the top line. Efforts to modernize its fleet are also encouraging.

New Downgrades

Strained Margins Worry Bed Bath & Beyond (BBBY) Investors

Per the Zacks analyst, Bed Bath & Beyond is grappling with margin issues for nine straight quarters now, due to higher cost of investments. Unfortunately, this is likely to continue in fiscal 2018.

Margin & Litigation Pressure Weigh on Deutsche Bank (DB)

Per the Zacks analyst, legal issues leading to high expenses remain a concern for Deutsche Bank. Further, low (and even negative) interest rate environment and a competitive landscape add to the woes.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Exxon Mobil Corporation (XOM) : Free Stock Analysis Report

 

Vmware, Inc. (VMW) : Free Stock Analysis Report

 

United Continental Holdings, Inc. (UAL) : Free Stock Analysis Report

 

The Walt Disney Company (DIS) : Free Stock Analysis Report

 

Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report

 

AbbVie Inc. (ABBV) : Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research

Source : https://finance.yahoo.com/news/top-analyst-reports-exxonmobil-disney-144702782.html

Thanks for visit my website
Top Analyst Reports for ExxonMobil, Disney & AbbVie
Top Research Reports for AT&T, Nike & Simon Property Group
Yes, ExxonMobil and Chevron are Still Distorting Climate Science
Top Analyst Reports for Apple, ExxonMobil, Citigroup & Amgen
ExxonMobil Pushes Back Against Reports It Buried Climate Science
Exclusive: Top Environmental Group Thinks the Exxon Climate Controversy Will Persuade Voters—And They're Putting Money Behind It
Top Stock Reports for Verizon, Eli Lilly & Accenture
ExxonMobil refutes report it has quit ALEC
ExxonMobil to consider barring anti-LGBT job discrimination
Why is ExxonMobil Still Funding Climate Science Denier Groups?